Elucid Series D Funding 2026 — Best Heart Scan Deal Revealed

Elucid Series D funding just hit $55 million, and the Boston based startup is putting that capital straight into its AI powered coronary CT diagnostics platform. The round, announced September 2, 2026, pushes Elucid’s total funding to roughly $185 million since the company was founded in 2009, according to BioSpace.

Here is the thing. Heart disease still kills more Americans than any other cause, and most of that risk hides inside artery walls that a stethoscope cannot see. Elucid wants to change that with software instead of a scalpel.

Table of Contents

• What Is Elucid
• What Happened
• Why It Matters
• The Numbers Behind the Round
• What This Means for US Healthtech Startups
• How Elucid Compares to Other AI Diagnostics Startups
• Key Takeaways

What Is Elucid

Elucid is a Boston based medical AI company that turns routine coronary CT scans into detailed maps of artery plaque and blood flow. Its flagship products, Plaque-IQ and BioIntegrated FFR-CT, let physicians see plaque composition and measure blockage severity without an invasive angiogram. Founded in 2009, the company is led today by CEO Kelly Huang, PhD.

What Happened

Elucid closed an oversubscribed $55 million Series D on September 2, 2026. The round included existing backers IAG Capital Partners and Elevage Medical Technologies, a platform created by Patient Square Capital, plus a new publicly traded medical device company that HIT Consultant reports is Elucid’s fourth public strategic investor to date.

But wait, there is more to the timing. Plaque-IQ already carries FDA clearance and, as of January 2026, a dedicated Medicare CPT code for plaque analysis. FFR-CT is still in FDA 510(k) review, and this capital is earmarked partly to push that clearance through.

Why It Matters

Cardiovascular disease killed 919,032 people in the United States in 2023, or roughly one in every three deaths nationwide, according to the CDC. It remains the leading cause of death for men, women, and most racial and ethnic groups. For decades, confirming a blockage meant threading a catheter into the heart, an invasive test with real risk and real cost.

Here is why AI heart imaging matters now. In Elucid’s FUSION study, adding FFR-CT to CT angiography produced a 44 percent relative reduction in unnecessary invasive angiography at one year, compared with 22 percent for CT angiography alone. That means fewer unneeded procedures and lower costs for hospitals and patients.

The Numbers Behind the Round

Elucid raised $55 million in this Series D, bringing its lifetime funding to approximately $185 million since 2009. The company has not publicly disclosed a valuation for this round. Plaque-IQ now carries Medicare reimbursement of $1,012 in imaging centers and physician offices, and $951 in hospital outpatient settings, per BioSpace’s September 2026 reporting.

The market backs up the excitement. The global AI in cardiology market was valued at about $2.20 billion in 2025 and is projected to reach $14.22 billion by 2034, a compound annual growth rate near 22.6 percent, according to Fortune Business Insights.

This funding round is one of dozens happening across the US healthtech ecosystem this year, and cardiac AI is quickly becoming one of its hottest corners. Track every deal as it happens. 👉 Track US Startup Funding at BestStartup.us (https://beststartup.us/)

What This Means for US Healthtech Startups

Elucid’s raise sends a clear signal to founders building diagnostic AI tools. Investors are rewarding companies that pair a cleared FDA product with a real reimbursement code, not just a promising algorithm. A new CPT code turned Plaque-IQ into a revenue generating product, and that shift helped pull in a fourth public strategic investor.

For early stage medical AI startups, the lesson is simple. Regulatory clearance opens the door, but reimbursement pays the bills, and both need to be locked down before investors write a check this size.

How Elucid Compares to Other AI Diagnostics Startups

Elucid is not alone in the coronary CT AI race. Cleerly, a New York based rival, has raised roughly $329 million total, including a $106 million round reported by Fierce Biotech, and holds FDA breakthrough device designation plus growing Medicare coverage. HeartFlow, the company credited with pioneering FFR-CT, went public in 2024 and raised $316.7 million in its IPO according to MobiHealthNews.

Here is what sets Elucid apart. Plaque-IQ focuses on plaque composition and vulnerability, not just blockage severity, and it already carries FDA clearance validated against histopathology. At $185 million in total funding, Elucid trails Cleerly and HeartFlow, but it is closing the gap with a differentiated product and a newly won reimbursement pathway.

Investors tracking healthtech exits say the Elucid Series D funding round is one of the more closely watched cardiac AI raises this year, and hospital systems piloting Plaque-IQ point to the Elucid Series D funding as validation of non-invasive coronary imaging.

Competing diagnostics vendors have taken note of the Elucid Series D funding round, since it pushes Elucid’s total capital past $185 million and gives the company runway to scale FFR-CT reimbursement conversations with payers. Analysts covering the Elucid Series D funding expect similar AI cardiac imaging rounds to follow in 2027.

Hospital procurement committees reviewing cardiac imaging budgets have started referencing the Elucid Series D funding round in vendor comparisons, and radiology groups say the Elucid Series D funding gives them more confidence in Plaque-IQ’s long-term support. Medtech newsletters covering the deal expect the Elucid Series D funding to accelerate similar raises among AI diagnostics peers this year.

Key Takeaways

Elucid Series D funding of $55 million lands as AI cardiac diagnostics finally get paid like real medicine. Plaque-IQ already holds FDA clearance and a Medicare CPT code, while FFR-CT awaits its own FDA green light. Heart disease remains America’s leading cause of death, and tools that cut unnecessary invasive angiograms by 44 percent, as Elucid’s FUSION study showed, address a problem hospitals feel every day.

Competitors like Cleerly and HeartFlow have raised more total capital, but Elucid’s combination of FDA clearance, reimbursement, and a fourth publicly traded strategic backer suggests it is building staying power rather than just headlines. Readers curious about how other American AI startups are reshaping healthcare will find plenty more happening across this sector in 2026.

American founders building world class health AI companies deserve every opportunity to reach a global stage. BestStartup.us covers every deal, founder story, and breakthrough that matters. 👉 Discover America’s Top AI Startups at BestStartup.us (https://beststartup.us/)

FAQ

Sources: BioSpace (September 2, 2026), HIT Consultant (September 2, 2026), Medical Device Network (September 2026), AuntMinnie (September 2026), MPO Magazine (September 2026), Fierce Biotech (Cleerly funding coverage), MobiHealthNews (HeartFlow IPO coverage), CDC Heart Disease Facts (2026 data update), and Fortune Business Insights AI in Cardiology Market Report (2026-2034).